The Experts below are selected from a list of 72 Experts worldwide ranked by ideXlab platform
Qixin Zheng - One of the best experts on this subject based on the ideXlab platform.
-
A therapeutic delivery system for chronic osteomyelitis via a multi-Drug Implant based on three-dimensional printing technology
Journal of biomaterials applications, 2016Co-Authors: Qixin Zheng, Zhaohui ChengAbstract:Chronic osteomyelitis is difficult to be cured and often relapses, which presents to be a great challenge to clinicians. We conducted this original study to explore the efficiency of therapeutic alliance for chronic osteomyelitis by a multi-Drug Implant based on three-dimensional printing technology. We designed and fabricated preciously a multi-Drug Implant with a multi-layered concentric cylinder construction by three-dimensional (3D) printing technology. Levofloxacin and tobramycin were incorporated into the Drug Implant in a specific sequence. The Drug release property of the Drug Implant was assayed in vitro We also developed an animal model of chronic osteomyelitis to estimate the effect of the 3D printed multi-Drug Implant. The results showed that the multi-Drug Implant had a sustained and programmed Drug release property. Levofloxacin and tobramycin which were released from the multi-Drug Implant worked in tandem to enhance pharmacodynamic action which was similar to a tumor chemotherapy program and were sufficient to treat chronic osteomyelitis. These findings imply that the administration of 3D printed multi-Drug Implant would be a potential therapeutic method for chronic osteomyelitis. Further studies are required.
-
The controlled-releasing Drug Implant based on the three dimensional printing technology: Fabrication and properties of Drug releasing in vivo
Journal of Wuhan University of Technology-Mater. Sci. Ed., 2009Co-Authors: Qixin Zheng, Xiaodong Guo, Weidong HuangAbstract:Three dimensional (3D) printing technology was utilized to fabricate a new type of Drug Implant with complicated architectures, employing levofloxacin (LVFX) and rifampicine (RFP) as model Drugs. The prepared Drug Implant prototype consists of a double-layer structure, of which the upper region is a reservoir system containing RFP and the lower region is a matrix one containing LVFX. The release test in vivo revealed that LVFX was released in the early stage; no RFP was detected until 8th day; both of them continuously released more than 6 weeks. Therefore, 3D printing technology provides a precise and feasible method to fabricate a controlled-releasing Drug Implant with complicated architectures and this Drug Implant may present a new strategy for the prophylaxis and treatment of bone diseases such as combined bone infections and bone tuberculosis in the near future.
-
A programmed release multi-Drug Implant fabricated by three-dimensional printing technology for bone tuberculosis therapy
Biomedical materials (Bristol England), 2009Co-Authors: Qixin Zheng, Xiaodong Guo, Jianhua Sun, Yudong LiuAbstract:In the world, bone tuberculosis is still very difficult to treat and presents a challenge to clinicians. In this study, we utilized 3D printing technology to fabricate a programmed release multi-Drug Implant for bone tuberculosis therapy. The construction of the Drug Implant was a multi-layered concentric cylinder divided into four layers from the center to the periphery. Isoniazid and rifampicin were distributed individually into the different layers in a specific sequence of isoniazid–rifampicin–isoniazid–rifampicin. The Drug release assays in vitro and in vivo showed that isoniazid and rifampicin were released orderly from the outside to the center to form the multi-Drug therapeutic alliance, and the peak concentrations of Drugs were detected in sequence at 8 to 12 day intervals. In addition, no negative effect on the proliferation of rabbit bone marrow mesenchymal stem cells was detected during the cytocompatibility assay. Due to its ideal pharmacologic action and cytocompatibility, the programmed release multi-Drug Implant with a complex construction fabricated by 3D printing technology could be of interest in prevention and treatment of bone tuberculosis.
Zhaohui Cheng - One of the best experts on this subject based on the ideXlab platform.
-
A therapeutic delivery system for chronic osteomyelitis via a multi-Drug Implant based on three-dimensional printing technology
Journal of biomaterials applications, 2016Co-Authors: Qixin Zheng, Zhaohui ChengAbstract:Chronic osteomyelitis is difficult to be cured and often relapses, which presents to be a great challenge to clinicians. We conducted this original study to explore the efficiency of therapeutic alliance for chronic osteomyelitis by a multi-Drug Implant based on three-dimensional printing technology. We designed and fabricated preciously a multi-Drug Implant with a multi-layered concentric cylinder construction by three-dimensional (3D) printing technology. Levofloxacin and tobramycin were incorporated into the Drug Implant in a specific sequence. The Drug release property of the Drug Implant was assayed in vitro We also developed an animal model of chronic osteomyelitis to estimate the effect of the 3D printed multi-Drug Implant. The results showed that the multi-Drug Implant had a sustained and programmed Drug release property. Levofloxacin and tobramycin which were released from the multi-Drug Implant worked in tandem to enhance pharmacodynamic action which was similar to a tumor chemotherapy program and were sufficient to treat chronic osteomyelitis. These findings imply that the administration of 3D printed multi-Drug Implant would be a potential therapeutic method for chronic osteomyelitis. Further studies are required.
Yudong Liu - One of the best experts on this subject based on the ideXlab platform.
-
A programmed release multi-Drug Implant fabricated by three-dimensional printing technology for bone tuberculosis therapy
Biomedical materials (Bristol England), 2009Co-Authors: Qixin Zheng, Xiaodong Guo, Jianhua Sun, Yudong LiuAbstract:In the world, bone tuberculosis is still very difficult to treat and presents a challenge to clinicians. In this study, we utilized 3D printing technology to fabricate a programmed release multi-Drug Implant for bone tuberculosis therapy. The construction of the Drug Implant was a multi-layered concentric cylinder divided into four layers from the center to the periphery. Isoniazid and rifampicin were distributed individually into the different layers in a specific sequence of isoniazid–rifampicin–isoniazid–rifampicin. The Drug release assays in vitro and in vivo showed that isoniazid and rifampicin were released orderly from the outside to the center to form the multi-Drug therapeutic alliance, and the peak concentrations of Drugs were detected in sequence at 8 to 12 day intervals. In addition, no negative effect on the proliferation of rabbit bone marrow mesenchymal stem cells was detected during the cytocompatibility assay. Due to its ideal pharmacologic action and cytocompatibility, the programmed release multi-Drug Implant with a complex construction fabricated by 3D printing technology could be of interest in prevention and treatment of bone tuberculosis.
Xiaodong Guo - One of the best experts on this subject based on the ideXlab platform.
-
The controlled-releasing Drug Implant based on the three dimensional printing technology: Fabrication and properties of Drug releasing in vivo
Journal of Wuhan University of Technology-Mater. Sci. Ed., 2009Co-Authors: Qixin Zheng, Xiaodong Guo, Weidong HuangAbstract:Three dimensional (3D) printing technology was utilized to fabricate a new type of Drug Implant with complicated architectures, employing levofloxacin (LVFX) and rifampicine (RFP) as model Drugs. The prepared Drug Implant prototype consists of a double-layer structure, of which the upper region is a reservoir system containing RFP and the lower region is a matrix one containing LVFX. The release test in vivo revealed that LVFX was released in the early stage; no RFP was detected until 8th day; both of them continuously released more than 6 weeks. Therefore, 3D printing technology provides a precise and feasible method to fabricate a controlled-releasing Drug Implant with complicated architectures and this Drug Implant may present a new strategy for the prophylaxis and treatment of bone diseases such as combined bone infections and bone tuberculosis in the near future.
-
A programmed release multi-Drug Implant fabricated by three-dimensional printing technology for bone tuberculosis therapy
Biomedical materials (Bristol England), 2009Co-Authors: Qixin Zheng, Xiaodong Guo, Jianhua Sun, Yudong LiuAbstract:In the world, bone tuberculosis is still very difficult to treat and presents a challenge to clinicians. In this study, we utilized 3D printing technology to fabricate a programmed release multi-Drug Implant for bone tuberculosis therapy. The construction of the Drug Implant was a multi-layered concentric cylinder divided into four layers from the center to the periphery. Isoniazid and rifampicin were distributed individually into the different layers in a specific sequence of isoniazid–rifampicin–isoniazid–rifampicin. The Drug release assays in vitro and in vivo showed that isoniazid and rifampicin were released orderly from the outside to the center to form the multi-Drug therapeutic alliance, and the peak concentrations of Drugs were detected in sequence at 8 to 12 day intervals. In addition, no negative effect on the proliferation of rabbit bone marrow mesenchymal stem cells was detected during the cytocompatibility assay. Due to its ideal pharmacologic action and cytocompatibility, the programmed release multi-Drug Implant with a complex construction fabricated by 3D printing technology could be of interest in prevention and treatment of bone tuberculosis.
Helen M Burt - One of the best experts on this subject based on the ideXlab platform.
-
a polymer based Drug delivery system for the antineoplastic agent bis maltolato oxovanadium in mice
British Journal of Cancer, 1997Co-Authors: John K Jackson, W Min, T Cruz, S Cindric, L Arsenault, D D Von Hoff, D Degan, W L Hunter, Helen M BurtAbstract:Using vanadyl sulphate, sodium orthovanadate or bis(maltolato)oxovanadium (BMOV), Cruz TF, Morgan A, Min W (1995, Mol Cell Biochem 153: 161-166) have recently demonstrated the antineoplastic effects of vanadium in mice. In this study, the antineoplastic effects of BMOV against human tumour cell lines was confirmed, and this effect was shown to depend on the prolonged exposure of the cells to the Drug. We have investigated a polymeric Drug delivery system for the sustained delivery of BMOV as an antineoplastic agent in mice. The objective was to design and evaluate an injectable polymer-BMOV paste that would act as a Drug Implant for the slow but sustained release of BMOV in the mice. In vitro studies showed that the biodegradable polymer poly (Ghlr epsilon epsilon-caprolactone) (PCL) released BMOV in a sustained manner with rates of Drug release increasing with increased loading of the Drug in the polymer. In vivo studies showed that PCL-BMOV paste Implants produced a concentration-dependent inhibition of MDAY-D2 tumour growth via systemic Drug delivery. Further in vivo studies showed that 5% BMOV-loaded PCL (containing 20% methoxypolyethylene glycol) was effective in preventing tumour regrowth of resected RIF tumour masses in mice when the PCL-BMOV paste was applied to the resected site for localized Drug delivery. The results confirm the potential of vanadium as an antineoplastic agent and show that the injectable PCL-BMOV formulation releases a chemotherapeutic dose of vanadium for the systemic treatment of whole tumours as well as the localized treatment of resected RIF tumours.
